68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer

Abdominal Imaging

Volumn 40, Issue 6, 2015, Pages 1769-1771

  Eiber, Matthias ^a   Nekolla, Stephan G ^a   Maurer, Tobias ^a   Weirich, Gregor ^a   Wester, Hans Jürgen ^b   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

68Ga PSMA; Multiparametric analysis; PET MR; Prostate cancer; Tumor biology

Indexed keywords

FORMALDEHYDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; TRACER; UNCLASSIFIED DRUG; EDETIC ACID; GALLIUM; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; OLIGOPEPTIDE;

AGED; ARTICLE; CANCER STAGING; CASE REPORT; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MALE; MULTIMODAL IMAGING; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; WHOLE BODY IMAGING; ANALOGS AND DERIVATIVES; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE CARE; PROCEDURES; PROSTATIC NEOPLASMS; SCINTISCANNING;

AGED; ANTIGENS, SURFACE; EDETIC ACID; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROSTATIC NEOPLASMS;

EID: 84938981713     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-014-0301-z     Document Type: Article

References (6)

1. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Linhart HG (2014) Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 41:11–20
2. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur. J. Nucl. Med. Mol. Imaging. 41:887–897
3. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM (2012) [68 Ga] Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18 F-FECH. Eur. J. Nucl. Med. Mol. Imaging 39(6):1085–1086
4. Metz S, Ganter C, Lorenzen S, et al. (2010) Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nuc Med 51:1691–1698
5. Chen Y-J, Chu W-C, Pu Y-S, et al. (2012) Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J. Magn. Reson. Imaging JMRI. 36:912–919
6. Oto A, Yang C, Kayhan A, et al. (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am. J. Roentgenol 197:1382–1390